<DOC>
	<DOCNO>NCT00004056</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy follow melphalan peripheral stem cell transplantation treat child newly diagnose acute myeloid leukemia treat previously .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Melphalan Peripheral Stem Cell Transplantation Treating Children With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility toxicity time sequential remission induction consolidation child newly diagnose acute myeloid leukemia . II . Determine feasibility toxicity single high dose melphalan peripheral blood stem cell rescue follow intense time sequential induction consolidation child . OUTLINE : This multicenter study . Remission induction : Patients receive daunorubicin IV 15 minute day 1-3 , cytarabine IV continuously day 1-7 , oral thioguanine daily day 1-7 , cytarabine intrathecally ( IT ) day 1 . Cytarabine IV 3 hour administer every 12 hour day 10-12 . Filgrastim ( G-CSF ) administer IV subcutaneously ( SQ ) begin day 13 continue blood count recover . On approximately day 28 , patient undergo bone marrow aspirate biopsy ass response . Patients attain M1 M2a status proceed consolidation , 5/5 6/6 HLA match sibling donor available , proceed allogeneic bone marrow transplantation . Patients great 25 % blast go study . Consolidation 1 : Patients receive daunorubicin IV 15 minute day 1 2 , cytarabine IV 3 hour every 12 hour day 1 , 2 , 8 , 9 , asparaginase day 2 9 . G-CSF IV SQ begin day 10 continue blood count recover . Consolidation 2 : Patients receive cytarabine IV 3 hour every 12 hour day 1 , 3 , 5 . G-CSF IV SQ begin day 6 continue blood count recover . Peripheral blood stem cell ( PBSC ) collect second course consolidation . Consolidation 3 : Treatment repeat consolidation 1 . Patients remain morphologic remission consolidation 3 proceed therapy . Patients receive melphalan IV 30 minute day -2 , PBSC reinfused day 0 . G-CSF IV SQ begin day 1 continue blood count recover . Patients follow every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , previously untreated primary acute myeloid leukemia ( AML ) Isolated granulocytic sarcoma ( myeloblastoma ) allow Patients cytopenias bone marrow blast great 5 % le 30 % eligible karyotypic abnormality characteristic de novo AML ( ( 8 ; 21 ) , inv16 , ( 9 ; 11 ) , etc . ) OR unequivocal presence megakaryoblasts No acute promyelocytic leukemia ( M3 ) No Down syndrome PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL Uric acid great 8.0 mg/dL Cardiovascular : Cardiac function normal echocardiogram Pulmonary : No uncontrolled , life threaten pneumonia Other : No uncontrolled , life threaten sepsis meningitis Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>